.alpha.-synuclein super-mutants accelerate .alpha.-synuclein aggregation
US6184351A · kind A · utility
5Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 24, 1999 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Sep 24, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder which is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major component of which are filaments consisting of .alpha.-synuclein. The present invention provides .alpha.-synuclein mutations which accelerate .alpha.-synuclein aggregation and can thus be utilized for transgenic animal production and generation of the first progressive PD model. Also provided is an in vitro aggregation assay which can be utilized to identify .alpha.-synuclein nucleation inhibitors for the treatment of PD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.